Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
- Authors: Kit OI1, Vladimirova LY1, Abramova NA1, Storozhakova AE1, Popova IL1, Tikhanovskaya NM1, Lyaynova AA1, Ryadinskaya LA1
-
Affiliations:
- Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federation
- Issue: Vol 19, No 2 (2017)
- Pages: 42-46
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27142
- ID: 27142
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
O I Kit
Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federation
Email: rnioi@list.ru
д-р мед. наук, проф., дир. ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
L Y Vladimirova
Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federationд-р мед. наук, проф., рук. отд. лекарственного лечения опухолей ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
N A Abramova
Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federationканд. мед. наук, ст. науч. сотр. отд. лекарственного лечения опухолей ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
A E Storozhakova
Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federationканд. мед. наук, врач отд-ния противоопухолевой лекарственной терапии №2 ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
I L Popova
Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federationканд. мед. наук, ст. науч. сотр. отд. лекарственного лечения опухолей ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
N M Tikhanovskaya
Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federationканд. мед. наук, врач-онколог отд-ния противоопухолевой лекарственной терапии № 1 ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
A A Lyaynova
Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federationврач-онколог отд-ния противоопухолевой лекарственной терапии № 1 ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
L A Ryadinskaya
Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federationканд. мед. наук, врач-онколог отд-ния противоопухолевой лекарственной терапии № 1 ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
References
- Jemal A. Global cancer statistics. CA Cancer J Clin 2011; 2 (61): 69-90.
- Кит О.И., Владимирова Л.Ю., Абрамова Н.А. и др. Опыт применения моноклональных антител - блокаторов EGFR в лечении метастатического колоректального рака. Фарматека. 2015; 18 (311): 24-8.
- Van Cutsem E, Humblet Y, Gruenberger T et al. Cetuximab dose - escalation study in patients with nCRC with no or slight skin reaction on cetuximab standard dose treatment (EVEREST): preliminary PK and efficacy date of a randomized study. Proc. of ASCO 2007. Abstract 237.
- Van Cutsem E, Peeters M, Siena S et al. Open - label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy - refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-64.
- Vladimirova L.Y, Kit O.I, Nikipelova E.A, Abramova N.A. Results of monoclonal antibodies against EGFR-receptors application in patients with metastic colorectal cancer. J Clin Oncol 2013; 31 (15S) part I of II: 800S.
- Price T.J, Peeters M, Kim T.W et al. Panitumumab versus cetuximab in patients with chemotherapy - refractory wild - type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open - label, non - inferiority phase 3 study. Lancet Oncol 2014; 15 (6): 569-79.
- Khattak M.A, Martin H, Davidson A, Phillips M. Role of first - line antiepidermal growth factor receptor therapy compared with anti - vascular endothelial growth factor therapy in advanced colorectal cancer: a meta - analysis of randomized clinical trials. Clin Colorectal Cancer 2015; 14 (2): 81-90.
- Kopetz S, Hoff P.M, Morris J.S et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010; 28 (3): 453-9.
- Wilhelm S.M, Dumas J, Adnane L et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129 (1): 245-55.
- Grothey A, Van Catsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo - controlled, phase 3 trial. Lancet 2013; 381: 303-12.
- Li J, Qin S, Xu R et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, doubleblind, placebo - controlled, phase 3 trial. Lancet Oncol 2015; 16: 619-29.
- Артамонова Е.В. Новые возможности терапии интенсивно - предлеченных пациентов с метастатическим колоректальным раком. Мед. совет. 2016; 10: 24-32.
- Секачева М.И., Багмет Н.Н. Применение регорафениба при метастатическом колоректальном раке в реальной клинической практике // Современная онкология. 2016; 18 (3): 43-7.
- Van Cutsem E, Ciardiello F, Seitz J-F et al. Results from the large, open - label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. Ann Oncol 2015; 26 (Suppl. 4): Iv117-iv121.
- Abou-Elkacem L, Arns S, Brix G et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 2013; 12 (7): 1322-31.